[1]徐廷斌,孙振永,梁显湛,等.酒石酸美托洛尔联合脑心通治疗冠心病合并高血压患者临床疗效分析▲[J].内科,2020,15(06):686-689.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2020.06.15]
　XU Tingbin,SUN Zhenyong,LIANG Xianzhan,et al.Clinical efficacy analysis of metoprolol tartrate combined with Naoxintong in the treatment of patients with coronary heart disease combined with hypertension[J].Internal Medicine of China,2020,15(06):686-689.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2020.06.15]
点击复制

酒石酸美托洛尔联合脑心通治疗冠心病合并高血压患者临床疗效分析▲()
分享到：

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:
15卷
期数:
2020年06
页码:
686-689
栏目:
论著
出版日期:
2020-12-31

文章信息/Info

Title:
Clinical efficacy analysis of metoprolol tartrate combined with Naoxintong in the treatment of patients with coronary heart disease combined with hypertension
文章编号:
1673-7768（2020）06-0686-04
作者:
徐廷斌1; 孙振永1; 梁显湛1; 张春洪2; 廖业敏1
广东省阳西县人民医院，1 心血管内科，2 中医科，阳江市529800
Author(s):
XU Tingbin1;  SUN Zhenyong1;  LIANG Xianzhan1;  ZHANG Chunhong2;  LIAO Yemin1
1 Department of Cardiovascular Medicine, 2 Department of Traditional Chinese Medicine, Yangxi County People′s Hospital, Yangjiang 529800, Guangdong Province, China
关键词:
冠心病; 高血压; 脑心通; 酒石酸美托洛尔
Keywords:
Coronary heart disease;  Hypertension;  Naoxintong;  Metoprolol tartrate
分类号:
R 544.1；R 541
DOI:
DOI：10.16121/j.cnki.cn45-1347/r.2020.06.15
文献标志码:
A
摘要:
目的探讨酒石酸美托洛尔联合脑心通治疗冠心病合并高血压患者的临床疗效。方法选取2017年2月至2019年3月我院收治的冠心病合并高血压患者92例为研究对象，按照患者就诊先后顺序分为观察组和对照组，每组46例。对照组患者给予酒石酸美托洛尔治疗，观察组患者给予酒石酸美托洛尔联合脑心通治疗，疗程8周。比较两组患者的临床疗效；比较两组患者治疗前后的血压、心功能、内皮功能；比较治疗期间两组患者的心血管不良事件发生情况。结果观察组患者的治疗总有效率（93.5%）高于对照组（78.3%），差异有统计学意义（P＜0.05）。治疗前，两组患者的收缩压、舒张压比较差异无统计学意义（P＞0.05）；治疗8周后，观察组患者的收缩压、舒张压低于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者的心功能指标水平比较差异无统计学意义（P＞0.05）；治疗8周后，观察组患者的左室收缩末期内径、左室舒张末期内径小于对照组，左室射血分数高于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者的血浆内皮素-1（ET-1）、一氧化氮（NO）水平比较差异无统计学意义（P＞0.05）；治疗8周后，观察组患者的ET-1水平低于对照组，NO水平高于对照组，差异有统计学意义（P＜0.05）。治疗期间两组患者的心血管不良事件发生率比较差异无统计学意义（P＞0.05）。结论酒石酸美托洛尔联合脑心通治疗冠心病合并高血压患者临床疗效显著，可明显降低血压，改善心功能和血管内皮功能，但不会增加心血管不良事件的发生。
Abstract:
ObjectiveTo explore the clinical efficacy of metoprolol tartrate combined with Naoxintong in the treatment of patients with coronary heart disease combined with hypertension. MethodsA total of 92 patients with coronary heart disease combined with hypertension who were admitted to our hospital from February 2017 to March 2019 were selected as the research objects, and they were divided into observation group and control group according to the sequence of their visits, with 46 cases in each group. The control group was treated with metoprolol tartrate, whereas the observation group was treated with metoprolol tartrate combined with Naoxintong, for an eight-week treatment course. The clinical efficacy, the blood pressure, cardiac function, and endothelial function before and after treatment, as well as the occurrence of adverse cardiovascular events during the treatment, were compared between the two groups. ResultsThe total effective rate of treatment in the observation group (93.5%) was higher than that in the control group (78.3%), and the difference was statistically significant (P＜0.05). There were no statistically significant differences in systolic and diastolic blood pressures between the two groups before treatment (P＞0.05). The systolic and diastolic blood pressures of the observation group were lower than those of the control group after 8 weeks of treatment, and the differences were statistically significant (P＜0.05). There were no statistically significant differences in the levels of cardiac function indexes between the two groups before treatment (P＞0.05); after 8 weeks of treatment, the left ventricular end-systolic diameter and left ventricular end-diastolic diameter of the observation group were smaller than those of the control group, whereas the left ventricular ejection fraction was higher than that of the control group, and the differences were statistically significant (P＜0.05). There were no statistically significant differences in the levels of Endothelin-1 (ET-1) and nitric oxide (NO) between the two groups before treatment (P＞0.05); after 8 weeks of treatment, the ET-1 level of the observation group was lower than that of the control group, and the NO level was higher than that of the control group, with statistically significant differences (P＜0.05). There was no statistically significant difference in the incidence of cardiovascular adverse events between the two groups during the treatment period (P＞0.05). ConclusionMetoprolol tartrate combined with Naoxintong has a significantly clinical effect for patients with coronary heart disease combined with hypertension, which can significantly decrease blood pressure, improve heart function and vascular endothelial function, but it will not increase the incidence of cardiovascular adverse events.

相似文献/References:

[1]杜建梅.冠心病患者血清同型半胱氨酸检测结果分析[J].内科,2014,(05):578.
[2]戢运春 王玮.阿托伐他汀联合依折麦布治疗早发冠心病急性心肌梗死临床研究[J].内科,2015,(01):8.[doi:03DOI：10.16121/j.cnki.cn45-1347/r.2015.01.03]
　JI Yun-chun,WANG Wei.Clinical observation on atorvastatin combined with ezetimibe for treatment of patients with early acute myocardial infarction[J].Internal Medicine of China,2015,(06):8.[doi:03DOI：10.16121/j.cnki.cn45-1347/r.2015.01.03]
[3]王兰勤.苯磺酸氨氯地平联合缬沙坦对长期透析伴高血压患者的治疗效果分[J].内科,2015,(01):19.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2015.01.08]
[4]林蓓佑.超声心动图与冠脉造影对冠心病诊断价值的对比研究[J].内科,2015,(01):67.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2015.01.28]
　[J].Internal Medicine of China,2015,(06):67.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2015.01.28]
[5]邓珊 翁保慧（审校）.脑卒中可干预性危险因素的研究现状[J].内科,2015,(01):99.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2015.01.43]
　[J].Internal Medicine of China,2015,(06):99.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2015.01.43]
[6]李继志 陈奕 黄智武 徐家志 杨振宇.广西合浦县农村居民高血压患病及危险因素调查分析[J].内科,2015,(02):241.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2015.02.43]
　[J].Internal Medicine of China,2015,(06):241.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2015.02.43]
[7]刘卫强.盐酸曲美他嗪治疗冠心病合并心功能不全临床疗效观察[J].内科,2014,(01):30.
　[J].Internal Medicine of China,2014,(06):30.
[8]关雪梅 寇翠兰.系统化健康教育对提高高血压患者自我管理疾病能力效果观察[J].内科,2014,(01):34.
　[J].Internal Medicine of China,2014,(06):34.
[9]韦联章.高血压患者伴发快速房性心律失常与左房室重塑关系的临床分析[J].内科,2014,(02):162.
　[J].Internal Medicine of China,2014,(06):162.
[10]詹秀娥 乔彩萍.赖诺普利与氨氯地平对老年性高血压患者左心室质量及舒张功能影响的Meta分析[J].内科,2014,(03):270.
　ZHAN Xiu-e,QIAO Cai-ping.The meta-analysis of the effects of lisinopril versus amlodipine on left ventricular mass and diastolic function in elderly patients with hypertension[J].Internal Medicine of China,2014,(06):270.
[11]王建全.复方丹参滴丸预防冠心病合并高血压患者心脑血管不良事件发生的临床效果观察[J].内科,2013,(05):482.
　[J].Internal Medicine of China,2013,(06):482.
[12]杜永成,李黎明,文乾灵,等.冠心病发病危险因素研究分析[J].内科,2016,(01):29.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2016.01.10]
　DU Yong-cheng,LI Li-ming,WEN Quan-ling,et al.Study on risk factors of coronary heart disease[J].Internal Medicine of China,2016,(06):29.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2016.01.10]
[13]郑伊颖,黄德华,黄晓渝,等.超敏C反应蛋白和同型半胱氨酸与高血压合并冠心病发生发展的关系研究▲[J].内科,2017,12(01):58.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2017.01.18]
　[J].Internal Medicine of China,2017,12(06):58.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2017.01.18]
[14]冉现锁,习亚军,马楠.氨氯地平阿托伐他汀钙片治疗高血压合并冠心病患者的疗效分析▲[J].内科,2017,12(06):807.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2017.06.26]
　[J].Internal Medicine of China,2017,12(06):807.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2017.06.26]
[15]钟红.针对性睡眠护理干预对心内科疾病患者睡眠质量的影响▲[J].内科,2018,13(02):265.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2018.02.41]
　[J].Internal Medicine of China,2018,13(06):265.[doi:DOI：10.16121/j.cnki.cn45-1347/r.2018.02.41]

备注/Memo

备注/Memo:
▲基金项目：阳江市科技计划项目〔阳科通（2019）166〕
更新日期/Last Update: 2021-01-11